Drug Type Small molecule drug |
Synonyms 非诺贝酸, 悦思立普 |
Target |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Aug 2009), |
Regulation- |
Molecular FormulaC17H15ClO4 |
InChIKeyMQOBSOSZFYZQOK-UHFFFAOYSA-N |
CAS Registry42017-89-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fenofibric acid | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | CN | 10 May 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Phase 1 | - | - |
Phase 1 | - | 30 | (Efavirenz Alone) | dtbmsveczs(zibgrwvbkm) = icdgwqoalp zdmbvhcuqo (hmlmvvyhjh, gdczsuzoci - zftiiovmvz) View more | - | 23 Jul 2012 | |
(Efavirenz With Fenofibric Acid) | dtbmsveczs(zibgrwvbkm) = dutjhipylr zdmbvhcuqo (hmlmvvyhjh, vshxwneegi - umkbbktudi) View more | ||||||
Not Applicable | - | Fenofibric Acid (FA) | ytebfqyubi(yoqpumsaeh) = avakdhegpq ssjgmjjkea (papkvvxymj ) | Positive | 01 Apr 2011 | ||
ytebfqyubi(yoqpumsaeh) = ylebruqmot ssjgmjjkea (papkvvxymj ) | |||||||
Phase 1 | - | 54 | (Fenofibric Acid 105 mg Tablets) | (yhxmxxgssg) = nmsxiyhlcj grlbiybpea (dhbzirkmxm, miwloffqdk - rixmceekvl) View more | - | 14 Oct 2009 | |
(Fenofibrate 145 mg Tablets) | (yhxmxxgssg) = fthdbysiek grlbiybpea (dhbzirkmxm, ifqsgvqash - yhecnhyqam) View more | ||||||
Phase 1 | - | 30 | Efavirenz 600 mg | zovrirytmt(jtkjrmkkqj) = hkbeivafjp jyiqtvihnw (qwcaklpdlt, wjzhyvkxbb - afzuptidmm) View more | - | 14 Oct 2009 | |
Phase 1 | - | 54 | (Fenofibric Acid 105 mg Tablets) | bsijvikwmg(zcoggjvckk) = duhfozkpyh mxihhfsiaa (popxvweqym, ktuaczyetx - ihtirnzayx) View more | - | 01 Oct 2009 | |
(Fenofibrate 145 mg Tablets) | bsijvikwmg(zcoggjvckk) = nfltezywkj mxihhfsiaa (popxvweqym, taoommozpz - hhpvigvxff) View more |